No Data
No Data
Maravai LifeSciences To Host Earnings Conference Call on Wednesday, August 7, 2024
SAN DIEGO, July 10, 2024 (GLOBE NEWSWIRE) -- Maravai LifeSciences, Inc. (Maravai) (NASDAQ:MRVI), a global provider of life science reagents and services to researchers and biotech innovators, plans to announce its
Express News | Goldman Sachs Maintains Neutral on Maravai LifeSciences, Lowers Price Target to $7
Maravai LifeSciences Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 07/09/2024 -4.89% Goldman Sachs $8 → $7 Maintains Neutral 05/09/2024 35.87% Baird $8 → $10 Maintains
Maravai Lifesciences Releases 2023 Environmental, Social and Governance (ESG) Report
- Highlights progress across four priority areas and commitment to environmentally and socially responsible growth. - Conducted first stakeholder assessment to identify and prioritize ESG issues that are most important
Take Care Before Jumping Onto Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI) Even Though It's 35% Cheaper
Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI) shares have had a horrible month, losing 35% after a relatively good period beforehand. The drop over the last 30 days has capped off a tough year
Applied DNA and Alphazyme Conclude Linea(TM) RNAP Manufacturing Scale-up Project, Deliver Substantial Improvement in Linea(TM) IVT Platform Economics
- Project Results in over 70% Reduction in Linea RNAP Manufacturing Cost to Yield a Material Improvement in Linea IVT Platform Profitability -- Applied DNA Secures Commercial Linea RNAP Quantity Sufficient to Support